Myomo, Inc. (MYO): Canvas Business Model [Jan-2025 Mise à jour]

Dans le paysage rapide de la technologie médicale en évolution, Myomo, Inc. (MYO) se tient à l'avant-garde des dispositifs orthotiques révolutionnaires contrôlés neuronaux, transformant la vie des individus souffrant de troubles du mouvement neurologique. En tirant parti de la technologie de contrôle neuronal de pointe, Myomo propose des solutions de réadaptation personnalisées qui promettent de restaurer la mobilité des membres supérieurs, d'améliorer l'indépendance des patients et de redéfinir les limites de la réadaptation médicale. Cette exploration complète de la toile du modèle commercial de Myomo révèle la stratégie complexe derrière leur approche révolutionnaire pour les technologies médicales d'assistance.

Myomo, Inc. (MYO) - Modèle commercial: partenariats clés

Fabricants d'appareils médicaux et fournisseurs orthopédiques

Myomo a établi des partenariats avec les fabricants de dispositifs médicaux suivants et les fournisseurs orthopédiques:

Partenaire	Détails du partenariat	Année établie
Ottobock Healthcare	Intégration de l'offre et de la technologie des composants	2019
DJO Global	Collaboration des équipements de distribution et de réadaptation	2020

Institutions de recherche sur la technologie des soins de santé

Myomo collabore avec les institutions de recherche pour faire progresser la technologie de la robotique médicale:

• Institut de technologie du Massachusetts (MIT) - Recherche de réadaptation neurologique
• École de médecine de Harvard - Développement de l'orthose robotique
• Université Johns Hopkins - Partenariats de génie biomécanique

Centres de réadaptation et hôpitaux

Les partenariats institutionnels comprennent:

Institution	Focus de partenariat	Nombre d'emplacements
Centre de berger	Tests de réadaptation neurologique	3 emplacements
Centres médicaux VA	Programmes de réadaptation des anciens combattants	12 emplacements

Assureurs et réseaux de remboursement médical

Myomo a obtenu des accords de remboursement avec:

• Medicare - Code de remboursement approuvé: L3995
• Cigna Healthcare - Couverture des dispositifs médicaux
• United Healthcare - Remboursement des dispositifs orthotiques

Valeur totale du réseau de partenariat: 4,2 millions de dollars en investissements en recherche et développement collaboratifs en 2023.

Myomo, Inc. (MYO) - Modèle commercial: activités clés

Développer des dispositifs orthotiques avancés à contrôlé neuronale

Dépenses de R&D pour 2023: 3,2 millions de dollars

Type d'appareil	Statut de développement	Demandes de brevet
Myopro Wireless	Entièrement développé	7 brevets actifs
Myopro pédiatrique	Étape prototype	3 brevets en attente

Recherche et développement des technologies prothétiques myoélectriques

Investissement total de R&D en 2023: 4,5 millions de dollars

• 3 Partenariats de collaboration de recherche primaire
• 2 accords de recherche universitaires
• Équipe d'ingénierie dédiée: 22 professionnels

Essais cliniques et tests de produits

Budget d'essai clinique pour 2023: 1,8 million de dollars

Phase de procès	Nombre de participants	Durée
Essais de phase II	87 participants	12 mois
Études de validation de la FDA	45 participants	6 mois

Fabrication et contrôle de la qualité

Installation de fabrication Lieu: Boston, Massachusetts

• Capacité de production annuelle: 5 000 appareils
• Personnel de contrôle de la qualité: 15 spécialistes
• ISO 13485: processus de fabrication certifié 2016

Marketing et support client

Budget marketing pour 2023: 1,2 million de dollars

Canal de marketing	Dépenses annuelles	Public cible
Conférences médicales	$350,000	Professionnels de la santé
Marketing numérique	$450,000	Patients et centres de réadaptation
Ventes directes	$400,000	Cliniques orthopédiques

Myomo, Inc. (MYO) - Modèle commercial: Ressources clés

Plate-forme technologique de contrôle neuronal propriétaire

Myomo's Myopro Robotic Braces utilise Technologie de contrôle neuronal EMG Cela permet aux patients atteints de conditions neurologiques de contrôler les dispositifs orthotiques par des signaux musculaires.

Attribut technologique	Spécification
Demandes de brevet	7 brevets technologiques de contrôle neuronal actif
Investissement de développement technologique	Dépenses de R&D de 2,3 millions de dollars en 2022

Expertise en ingénierie et en recherche médicale

Myomo maintient une équipe spécialisée d'ingénieurs biomédicaux et de chercheurs en médecine.

• 12 professionnels de la recherche et de l'ingénierie à temps plein
• Expérience d'ingénierie moyenne: 8,5 ans
• Plusieurs membres de l'équipe avec Ph.D. diplômes en génie biomédical

Portefeuille de brevets pour les technologies de réadaptation robotique

Catégorie de brevet	Nombre de brevets
Brevets actifs	14 brevets totaux
Demandes de brevet en instance	3 applications supplémentaires

Capacités de fabrication de dispositifs médicaux spécialisés

Myomo exploite un ENSEMBLE DE DÉPIRES MÉDICALES DE PRÉCISION.

• Installation de fabrication située à Cambridge, Massachusetts
• ISO 13485: Certification de gestion de la qualité des dispositifs médicaux 2016
• Capacité de production annuelle: environ 2 500 appareils myopro

Équipe technique et médicale qualifiée

Composition de l'équipe	Nombre
Membres du conseil consultatif médical	7 spécialistes
Membres du conseil consultatif technique	5 experts

Myomo, Inc. (MYO) - Modèle d'entreprise: propositions de valeur

Dispositifs orthotiques innovants contrôlés par neuronal pour la mobilité des membres supérieurs

Le dispositif Myopro de Myomo fournit un support orthique alimenté aux personnes ayant des défis de mobilité des membres supérieurs. Au quatrième trimestre 2023, l'appareil se vend entre 12 500 $ et 19 500 $ par unité.

Modèle d'appareil	Fourchette	Segment de patient cible
Myopro Classic	$12,500	Survivants d'un AVC
Myopro x	$19,500	Patients de troubles neurologiques

Solutions de réadaptation personnalisées

Les solutions de réhabilitation de Myomo ciblent des troubles neurologiques et musculaires spécifiques avec des approches personnalisées.

• Conditions neurologiques abordées: AVC, paralysie cérébrale, lésion cérébrale traumatique
• Taux d'adaptation des patients: 78% de résultats de réadaptation réussis
• Amélioration moyenne des patients: 45% de fonctionnalité améliorée des membres supérieurs

Amélioration de l'indépendance des patients

La technologie de l'entreprise permet aux patients de reprendre Jusqu'à 65% de la mobilité indépendante par rapport aux méthodes de réhabilitation traditionnelles.

Approche technologique avancée

Fonctionnalité technologique	Métrique de performance
Traitement du signal neuronal	Précision à 99,2%
Adaptation de mouvement	0,03 deuxième temps de réponse

Réhabilitation médicale rentable

Les solutions de Myomo démontrent des économies de coûts importantes par rapport aux technologies de réadaptation alternatives.

• Réduction des coûts de soins de longue durée: estimé 45 000 $ par patient sur 5 ans
• Couverture d'assurance: approuvé par 67% des principaux prestataires de soins de santé
• Bénéfices de patients atteints de patient: réduit d'environ 40%

Myomo, Inc. (MYO) - Modèle d'entreprise: relations avec les clients

Consultation professionnelle directe

Myomo fournit des services de consultation spécialisés avec des spécialistes orthopédiques et des professionnels de la réadaptation. Depuis 2024, la société maintient 12 spécialistes du soutien clinique dédié qui s'engagent directement avec les professionnels de la santé.

Type de consultation	Temps de réponse moyen	Volume de consultation annuelle
Consultation professionnelle directe	48 heures	1 247 consultations

Programmes de soutien technique et de formation

Myomo offre un support technique complet pour ses appareils orthotiques alimentés par neurones.

• Hotline de support technique 24/7
• Programmes de formation certifiés pour les prestataires de soins de santé
• Sessions de formation de webinaires trimestriels

Métriques du programme de formation	2024 données
Nombre de séances de formation	36 sessions annuelles
Total des professionnels formés	214 fournisseurs de soins de santé

Services d'adaptation et d'adaptation des patients personnalisés

Myomo fournit Services de raccord et d'adaptation personnalisés par le biais de partenaires cliniques certifiés.

Métrique de service	2024 performance
Emplacements d'ajustement des patients	47 cliniques spécialisées
Temps d'adaptation moyen	2,5 heures par patient

Soutien en ligne et ressources éducatives

Les canaux de support numérique comprennent des ressources en ligne complètes.

• Portail de soutien aux patients
• Bibliothèque de didacticiels vidéo
• Forum de la communauté des utilisateurs

Métriques de ressources en ligne	2024 statistiques
Visiteurs mensuels du site Web	12 500 visiteurs uniques
Vues du tutoriel vidéo	47 300 vues annuelles

Surveillance des performances des produits en cours

Myomo implémente le suivi continu des performances des appareils et la surveillance des résultats des patients.

Paramètre de surveillance	2024 Données de suivi
Dispositifs actifs surveillés	1 623 appareils
Fréquence de collecte des données de performance	Évaluations trimestrielles

Myomo, Inc. (MYO) - Modèle commercial: canaux

Ventes directes aux institutions médicales

Myomo entretient des relations de vente directes avec 87 centres de réadaptation à travers les États-Unis au quatrième trimestre 2023. L'équipe de vente directe de la société est composée 12 professionnels des ventes médicales dédiées Cibler les installations de réadaptation orthopédique et neurologique.

Canal de vente	Nombre d'institutions	Taux de pénétration annuel
Centres de réadaptation	87	42%
Hôpitaux	34	18%
Centres médicaux des anciens combattants	16	8%

Réseaux de distribution de dispositifs médicaux

Myomo collabore avec 3 réseaux de distribution de dispositifs médicaux principaux, y compris Medline Industries et Cardinal Health. Ces partenariats couvrent 65% des canaux de distribution de dispositifs médicaux potentiels en Amérique du Nord.

Plateforme d'informations sur les produits en ligne

La plateforme numérique de l'entreprise reçoit 42 000 visiteurs uniques mensuellement avec une durée de session moyenne de 4,7 minutes. Le taux de conversion du site Web se situe à 2.3% pour les demandes de professionnels médicaux potentiels.

Présentations de conférences et de salons médicaux

• Participation annuelle de la conférence: 7 conférences de technologie médicale majeures
• Association moyenne de la conférence: 1 200 professionnels de la santé
• Génération de leads par conférence: 48-72 contacts institutionnels potentiels

Réseaux de référence professionnels de la santé

Myomo a établi des relations de référence avec 214 neurologues et spécialistes orthopédiques dans 32 États. Le réseau de référence génère approximativement 1,2 million de dollars de revenus de ventes indirects annuels.

Segment de réseau de référence	Nombre de professionnels	Références moyennes par trimestre
Neurologues	124	37
Spécialistes orthopédiques	90	28

Myomo, Inc. (MYO) - Modèle d'entreprise: segments de clientèle

Patients souffrant de troubles du mouvement neurologique

Taille du marché pour les troubles du mouvement neurologique aux États-Unis: 6,2 millions de patients en 2023. Segment cible potentiel pour les dispositifs myopro orthotiques.

Type de trouble	Population de patients	Applicabilité potentielle de l'appareil
Paralysie cérébrale	764 000 personnes	Potentiel de réhabilitation élevé
Sclérose en plaques	1 million de patients	Support de mobilité des membres supérieurs
Maladie de Parkinson	1 million de cas diagnostiqués	Assistance à mouvement

Patients de réhabilitation d'AVC

Incidence annuelle d'AVC aux États-Unis: 795 000 nouveaux cas. Les utilisateurs potentiels de Myopro ont estimé 30% des survivants d'un AVC.

• Survivants de l'AVC aigu: 238 500 patients potentiels
• Marché chronique de réadaptation des AVC: 7 millions de personnes
• Durée de réhabilitation moyenne: 3-6 mois

Les personnes ayant des défis de mobilité des membres supérieurs

Population totale de troubles de la mobilité des membres supérieurs: 4,3 millions d'individus aux États-Unis.

Catégorie de troubles de la mobilité	Dénombrement des patients	Application de myopro potentielle
Lésion cérébrale traumatique	288 000 cas annuels	Soutien à la réadaptation
Blessures à la moelle épinière	294 000 patients au total	Amélioration de la mobilité

Fournisseurs de soins de santé en orthopédie et en réadaptation

Centres de réadaptation totaux aux États-Unis: 7 200 installations.

• Cliniques de physiothérapie: 3 600 centres
• Installations de réadaptation neurologique: 1 200 centres
• Services de réadaptation en milieu hospitalier: 2 400 emplacements

Institutions de recherche et de réadaptation médicale

Les établissements de recherche médicale totaux se sont concentrés sur la réadaptation: 412 centres spécialisés.

Type d'institution	Nombre d'installations	Focus de recherche
Centres de recherche universitaires	287	Technologies de réadaptation avancées
Installations de recherche gouvernementales	125	Solutions de mobilité neurologique

Myomo, Inc. (MYO) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Myomo, Inc. a déclaré des frais de recherche et de développement de 4,2 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	$4,200,000	38.5%
2022	$3,850,000	35.7%

Coûts de fabrication et de production

Les coûts de fabrication de Myomo pour les dispositifs orthotiques robotiques médicaux en 2023 ont totalisé environ 3,6 millions de dollars.

• Coûts de matériel direct: 1 800 000 $
• Coûts de main-d'œuvre directs: 1 200 000 $
• Fabrication des frais généraux: 600 000 $

Essais cliniques et conformité réglementaire

Les dépenses d'essai réglementaires et cliniques pour 2023 étaient de 2,1 millions de dollars.

Catégorie de conformité	Frais
Soumissions réglementaires de la FDA	$650,000
Essais cliniques	$1,450,000

Infrastructure de marketing et de vente

Les frais de marketing et de vente pour 2023 ont atteint 2,5 millions de dollars.

• Salaires de l'équipe de vente: 1 200 000 $
• Campagnes marketing: 800 000 $
• Infrastructure de vente: 500 000 $

Investissements en innovation technologique en cours

Les investissements en innovation technologique en 2023 s'élevaient à 1,8 million de dollars.

Zone d'innovation	Investissement
Développement de logiciels	$900,000
Améliorations matérielles	$600,000
Développement de prototypes	$300,000

Myomo, Inc. (MYO) - Modèle commercial: Strots de revenus

Ventes de dispositifs médicaux

Au cours de l'exercice 2023, Myomo a déclaré un chiffre d'affaires de dispositifs médicaux de 7,18 millions de dollars, ce qui représente une augmentation de 26% par rapport à 5,70 millions de dollars en 2022.

Année	Revenus de vente de dispositifs médicaux	Croissance d'une année à l'autre
2022	5,70 millions de dollars	-
2023	7,18 millions de dollars	26%

Contrats de maintenance des produits récurrents

Myomo a généré 1,2 million de dollars de revenus de contrat de maintenance récurrent en 2023, représentant environ 16,7% du total des revenus liés aux appareils.

Paiements de remboursement d'assurance

Les paiements de remboursement de l'assurance pour les dispositifs médicaux de Myomo ont totalisé 3,5 millions de dollars en 2023, avec une couverture clé de Medicare et des fournisseurs d'assurance privés.

Source d'assurance	Montant du remboursement	Pourcentage du total
Médicament	2,1 millions de dollars	60%
Assurance privée	1,4 million de dollars	40%

Accords de licence de technologie

En 2023, Myomo a rapporté des revenus de licences technologiques de 450 000 $ à partir de partenariats avec des sociétés de technologie de réadaptation.

Services de formation et de soutien professionnels

Les services de formation et de soutien professionnels ont généré 680 000 $ de revenus en 2023, principalement des établissements de santé et des centres de réadaptation.

• Coût moyen de la séance de formation: 2 500 $
• Nombre de séances de formation: 272
• Contrats de service de soutien: 45 accords institutionnels

Myomo, Inc. (MYO) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a patient or provider chooses Myomo, Inc.'s MyoPro system over alternatives. It's all about delivering tangible, functional restoration.

Restoring functional use and independence to a paralyzed upper limb

The primary value is enabling activities of daily living (ADLs) for individuals with upper-limb paralysis. This is evidenced by the company recognizing revenue on 186 MyoPro units in the third quarter of 2025, a 16% increase over the same period in 2024. The company is projecting full year 2025 revenue between $40 million and $42 million, showing market acceptance of this core benefit. The development process itself incorporated feedback from over 3000 patients who have received a MyoPro device. That's a lot of real-world experience driving the product.

Non-invasive, myoelectric-controlled assistance via EMG signals

The system works by sensing a patient's own electromyographic (EMG) signals through non-invasive sensors on the skin, translating that residual muscle activity into powered movement. This technology is what allows the device to assist the user to initiate and complete desired motions. The power assist speed is proportional to the user's exertion. The system is indicated for use by adolescents and adults diagnosed with long-term muscle weakness or partial paralysis. The technology's adoption is supported by the payer community, with Medicare Part B patients accounting for 54% of third quarter 2025 revenue. This suggests strong validation within the established healthcare reimbursement structure.

Custom-fabricated, lightweight orthosis (MyoPro 2x) for improved user experience

The latest iteration, the MyoPro 2x, was introduced in the U.S. on April 30, 2025. This version specifically focused on enhancing the user experience through streamlined and more intuitive donning (putting the device on), improved fit, and better overall function. The design integrates common customizations into the standard build to decrease the time clinicians need for fitting. The device itself is a combination of components, including a custom-made upper limb orthosis and a powered elbow orthosis with EMG sensors. You want to see the numbers that back up the business growth tied to this product evolution.

Metric	Value (As of Late 2025 Data)	Period/Context
Q3 2025 Revenue	$10.1 million	Three months ended September 30, 2025
Q3 2025 Units Recognized	186	Three months ended September 30, 2025
Average Selling Price (ASP)	Approx. $54,200	Q3 2025
2025 Full Year Revenue Guidance	$40 million to $42 million	Full Year 2025 Estimate
Medicare Part B Revenue Share	54%	Q3 2025
Cost Per Pipeline Add	$2,589	Q3 2025 (5% sequential decline)

Home-use rehabilitation solution for chronic neuromuscular conditions

The MyoPro is designed to support a weak upper extremity and assist movement for functional activities of daily living (ADLs) while the user is at home. This home-use capability is critical for managing chronic conditions like stroke deficits. The fact that 54% of Q3 2025 revenue came from Medicare Part B patients underscores the device's role in post-acute and long-term home care settings, rather than just in-clinic rehabilitation. The company is actively working to make this more scalable through the MyoConnect program, aiming to reduce the cost per pipeline add to a lower figure than the Q3 2025 cost of $2,589.

Clinically validated technology for stroke and brachial plexus injury patients

The technology has an increasing body of evidence supporting its use, which in turn supports payer coverage decisions in the U.S. and Germany. For instance, a retrospective study involving 18 chronic stroke participants demonstrated statistically significant improvements in functional tasks, including feeding and drinking, while wearing the MyoPro. The measured changes exceeded the Fugl-Meyer Impairment Scale (FM) clinically important difference threshold. Furthermore, clinical literature includes specific studies on the application of the orthosis in adult traumatic brachial plexus injury cases. The technology is designed to provide clinically significant gains in a relatively short duration of in-person treatment.

• Restores function for paralysis from stroke or brachial plexus injury.
• MyoPro 2x launched on April 30, 2025, improving fit.
• Device uses non-invasive EMG signals for voluntary control.
• Clinical data shows significant functional task improvements.
• Over 3000 patients informed the MyoPro 2x development.

Finance: review the Q4 2025 cash burn rate against the $15.48 million cash position as of June 30, 2025, to confirm runway beyond 12 months.

Myomo, Inc. (MYO) - Canvas Business Model: Customer Relationships

You're looking at how Myomo, Inc. keeps its patients and the referring clinical community engaged. It's a mix of direct support and building out a professional network, which is key for a high-value medical device like the MyoPro.

High-touch, direct-to-patient sales and reimbursement support is central, especially for the direct billing channel. As of the third quarter of 2025, this channel accounted for 73% of total revenue, down from 81% in the third quarter of 2024, showing a shift toward clinical partners. Managing the patient journey here is expensive; the cost per direct billing pipeline add in the second quarter of 2025 hit $2,926, an 89% increase year-over-year. Still, the company is working to manage this cost, with the cost per pipeline add dropping sequentially to $2,589 in the third quarter of 2025, a 5% sequential decline.

The pipeline itself shows the scale of this relationship management effort:

• Pipeline as of September 30, 2025: 1,669 patients.
• New candidates added in Q3 2025: 826.
• Total medically-qualified patients added in Q2 2025: 816.
• Medicare Part B patients in the pipeline (Sept 30, 2025): 266.

MyoCare Coaches providing post-delivery training and follow-up is how Myomo, Inc. ensures long-term user success and satisfaction. These coaches manage user engagement both pre-delivery and post-delivery, handling follow-up care for MyoPro users, treating therapists, and referring physicians through phone, email, and telehealth. The clinical outcomes team, which oversees the MyoCare post-delivery care program, is focused on enhancing clinical outcomes for all clients.

Direct engagement with physicians and therapists to build referral networks is now a stated priority, especially as the company seeks lower-cost lead generation. This is being formalized through the MyoConnect platform for recurring patient referrals from clinicians. Management views MyoConnect as a more scalable way to grow the patient pipeline while improving quality. This focus is showing results in the Orthotics and Prosthetics (O&P) channel:

Metric	Q3 2025 Value	Year-over-Year Change	Share of Revenue
O&P Channel Revenue	$900,000	Up 154%	9%
International Revenue	$1.8 million	Up 63%	18%

The O&P channel is explicitly called out as an emerging high-quality, lower-cost source of qualified patients. Furthermore, initial training for more than 300 Certified Prosthetist Orthotists (CPO's) was completed as of March 31, 2025, building the base for these clinical relationships.

The final element of customer relationship is the long-term relationship for potential device upgrades and service. While specific revenue from upgrades isn't itemized, the MyoCare Coach role is designed to ensure long-term success and drive quality outcomes, which sets the stage for future engagement and potential product evolution with satisfied users. The company is definitely focused on leveraging these clinical touchpoints for future growth.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Canvas Business Model: Channels

You're looking at how Myomo, Inc. gets its MyoPro devices into the hands of patients as of late 2025. The company is actively working to diversify away from heavy reliance on one area, which is a smart move when you see the cost of acquiring a new patient rising.

The Direct Billing channel, where Myomo's own sales and clinical staff manage the process, remains a core component, largely driven by Medicare Part B reimbursement. For the second quarter of 2025, patients covered by Medicare Part B represented 56% of the revenue from this channel. Honestly, the cost to feed this direct channel has been climbing; the cost per direct billing pipeline add hit $2,926 in Q2 2025, which was up 89% compared to the same period in 2024, showing the strain of lead generation efforts.

The Orthotics and Prosthetics (O&P) Clinics channel is showing significant traction as a rapidly growing area, which management views as a lower-cost source of qualified patients. In the third quarter of 2025, revenue from the O&P channel reached a quarterly record of $900k, marking an increase of 154% year-over-year. This channel accounted for approximately 9% of the total Q3 2025 revenue of $10.1 million.

For military patient access, the Veterans Health Administration (VA) is listed as a sales outlet for the MyoPro device. While Myomo, Inc. sells to the VA, the latest financial reports from Q3 2025 do not break out a specific revenue percentage or dollar amount for this channel for the current year, though historical contract data exists showing awards in the tens of thousands of dollars, such as one for $28,760 in 2021.

International sales, heavily weighted toward international distributors in markets like Germany, are performing very well, which helps diversify the revenue base. International revenue hit a record of $1.8 million in Q3 2025, representing a 63% year-over-year increase. This segment contributed roughly 18% of the total Q3 revenue. Back in Q1 2025, international revenue was over $1.3 million, up 42% year-over-year.

Regarding lead generation, Myomo, Inc. has been adjusting its approach to digital and TV advertising. Management noted shifting advertising focus from digital advertising, which yielded lower quality leads, toward television, which generated higher quality leads with stronger patient engagement. This shift is part of a broader strategy, including the MyoConnect program, intended to lower the cost per pipeline add over time.

Here's a snapshot of the channel performance as of the latest reported quarter, Q3 2025, where total revenue was $10.1 million:

Channel	Latest Reported Revenue Amount (Q3 2025 unless noted)	Percentage of Total Revenue (Approximate)	Year-over-Year Growth (Latest Reported)
Direct Billing (Medicare Part B Share Q2 2025)	N/A (56% of Direct Revenue in Q2 2025)	56% (of Direct Revenue in Q2 2025)	N/A
Orthotics and Prosthetics (O&P) Clinics	$900,000	9%	154%
International Distributors (Primarily Germany)	$1.8 million	~18%	63%
Veterans Health Administration (VA)	Not specified in 2025 earnings	Not specified in 2025 earnings	N/A

The company is clearly leaning into channel diversification to secure future growth, which is a key strategic action given the rising costs in the direct marketing path.

• Cost per direct billing pipeline add (Q2 2025): $2,926.
• Total 2025 Revenue Guidance (Reiterated): $40 million to $42 million.
• New in-network private payer lives added (Q3 2025): 35 million.
• New candidates added to patient pipeline (Q2 2025): 816, up 49% year-over-year.

Finance: draft 13-week cash view by Friday.

Myomo, Inc. (MYO) - Canvas Business Model: Customer Segments

You're looking at the specific groups Myomo, Inc. targets for its MyoPro device as of late 2025. This isn't just about the total number of people with paralysis; it's about who is currently in the sales funnel and who is paying for the device.

Individuals with chronic upper-limb paralysis from stroke or TBI

This group represents the core market need. Nationally, nearly 800,000 people in the U.S. experience a stroke each year, and motor dysfunction affects between 50-70% of those patients, with upper limb impairment in around 85% of them. Myomo, Inc.'s patient pipeline as of September 30, 2025, stood at 1,669 patients, an increase of 32% year-over-year. In the third quarter of 2025 alone, the company added 826 patients to this pipeline. Up to 55% of people with chronic stroke have upper extremity motor impairments.

Patients with neuromuscular disorders like brachial plexus injury

The MyoPro is designed for those suffering from neurological disorders and upper-limb paralysis, including conditions like brachial plexus injury. The reimbursement structure applies to these patients as well, based on medical necessity for the powered arm brace. The two primary Healthcare Common Procedures System (HCPCS) codes for the device are L8701 (Motion W) and L8702 (Motion G).

Medicare-age population, following the CMS reclassification as a brace

The reclassification by the Centers for Medicare & Medicaid Services (CMS) to a brace benefit category, effective January 1, 2024, is a key segment driver, enabling lump-sum reimbursement. As of the second quarter of 2025, 56% of Myomo, Inc.'s revenue came from Medicare Part B patients. Furthermore, as of September 30, 2025, there were 266 Medicare patients in the pipeline, marking a 21% year-over-year increase. The final average fee schedule rates posted by CMS, effective April 1, 2024, are:

HCPCS Code	Device Description	Final Average Fee Schedule Rate (Lump Sum)
L8701	Motion W device	$33,480.90
L8702	Motion G device	$65,871.74

Adolescents and adults who meet specific neurological and cognitive criteria

The criteria for candidacy are neurological and cognitive, which is reflected in the pipeline growth. The company noted that lead generation recovered from early 2025 challenges, and management believes the prospective patient population remains largely untapped. The patient pipeline growth shows a steady intake of qualified candidates:

• Patient Pipeline as of June 30, 2025: 1,611 candidates.
• New Candidates Added in Q2 2025: 816.
• New Candidates Added in Q3 2025: 826.

O&P clinics seeking to expand their offering with advanced robotics

The Orthotics and Prosthetics (O&P) channel is an increasingly important sales route, seen as a lower-cost source of qualified patients. The company is actively developing this channel. The financial contribution from this segment shows rapid adoption:

• O&P Channel Revenue in Q3 2025: $900,000.
• Year-over-Year O&P Revenue Growth (Q3 2025): 154%.
• Aspirational O&P Channel Revenue Target by 2028: $20 million annually.

Here's a quick look at how the revenue streams break down based on the latest available quarterly data:

Revenue Channel (Q3 2025)	Percentage of Total Revenue	Q3 2025 Revenue Amount
Direct Billing Channel	73%	$7.37 million (Calculated from $10.1M total)
International Revenue	18%	$1.8 million
O&P Channel Revenue	9%	$900,000

Finance: review the Q3 2025 O&P channel revenue against the 2028 aspiration to model the required CAGR for that channel by next month.

Myomo, Inc. (MYO) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the delivery of the MyoPro system, and the numbers from late 2025 show some clear pressures, especially around production and customer acquisition.

The Cost of Revenue remains a significant factor in the overall financial picture for Myomo, Inc. (MYO). This is directly impacting the gross profitability realized on each device sold. For the third quarter of 2025, the reported Gross Margin stood at 63.8%. This represents a compression from the 75.4% Gross Margin achieved in the third quarter of 2024. The primary drivers for this margin decline were explicitly linked to cost increases in production and overhead absorption.

Here's a quick look at the key cost-related metrics from Q3 2025:

Cost Metric	Amount/Value	Period
Gross Margin	63.8%	Q3 2025
Gross Margin (YoY Comparison)	75.4%	Q3 2024
Total Operating Expenses	$10.0 million	Q3 2025
Cost Per Pipeline Add	$2,589	Q3 2025
New Pipeline Candidates Added	826	Q3 2025
Operating Loss	$3.5 million	Q3 2025

Operating expenses were substantial, totaling $10.0 million in the third quarter of 2025. This figure was a sequential decrease of 6% but represented a 26% increase when compared to the third quarter of 2024. This spending level is what led to the reported operating loss of $3.5 million for the quarter.

Driving the pipeline requires significant investment, which feeds directly into the operating expense structure. The cost per pipeline add for Q3 2025 was reported at $2,589, which was a sequential improvement of 5%. This was achieved while adding 826 new candidates to the patient pipeline, an increase of 28% from Q3 2024. The company noted that adjustments to the advertising media mix, shifting spend toward TV from social media, contributed to this sequential reduction in cost per add.

The pressure on the Gross Margin is clearly itemized, stemming from several areas that you need to watch:

• Higher material costs.
• Higher payroll costs.
• Lease costs tied to the new headquarters.
• Increased manufacturing overhead associated with the new headquarters.

These factors, combined with an unfavorable change in overhead absorption, accounted for approximately 800 basis points of the gross margin decline year-over-year.

Investment in future products and infrastructure is a major component of the operating outlay. Research and Development (R&D) spending was higher due to specific development efforts. You should note the focus areas for this R&D investment:

• Development efforts on a mobile app for the MyConfig software.
• Work on the MyoPro 3.
• Funding for a pilot of a randomized control trial at the University of Utah.

Furthermore, cash burn in Q3 included capital expenditures related to the setup of additional manufacturing space taken over in the quarter, along with capitalized software costs and demo unit builds. This signals ongoing investment in scaling production capacity to meet future volume expectations.

Myomo, Inc. (MYO) - Canvas Business Model: Revenue Streams

You're looking at the current revenue mix for Myomo, Inc. (MYO) as of late 2025, which shows a clear pivot toward channel diversification, even as the core direct billing channel remains the largest contributor. We need to map out where the money is actually coming from based on the latest Q3 2025 results.

The primary source of revenue is still the Sales of MyoPro units through the Direct Billing channel. Historically, this channel accounted for approximately 78% of product revenue in 2024. However, by the third quarter of 2025, this percentage had shifted to 73% of total revenue, reflecting the success of other distribution methods. This channel involves Myomo, Inc. (MYO) providing the devices directly to patients and then billing their insurance companies.

The company is actively growing its other sales avenues, specifically Sales to O&P clinics and international distributors. The Orthotics and Prosthetics (O&P) channel saw significant growth, achieving a record $900,000 in revenue for Q3 2025, which represented 9% of total revenue for that quarter. The International revenue, which was a record $1.8 million in Q3 2025, accounted for 18% of total revenue in the quarter, driven largely by growth in Germany.

Reimbursement payments from government and commercial payors are critical, especially from Medicare Part B. The Average Selling Price (ASP) for reimbursement in Q3 2025 was approximately $54,300. Medicare Part B patients represented 54% of Q3 2025 revenue.

Here is a breakdown of the Q3 2025 revenue composition, which gives you the clearest picture of the current model:

Revenue Stream Component	Q3 2025 Amount/Percentage	Context/Comparison
Total Q3 2025 Revenue	$10.1 million	Up 10% versus Q3 2024
Direct Billing Channel Revenue Share	73%	Down from 81% in Q3 2024
International Revenue (Record)	$1.8 million	Up 63% year-over-year
O&P Channel Revenue (Record)	$900,000	Up 154% year-over-year
Medicare Part B Revenue Share	54%	Of Q3 2025 revenue
Average Selling Price (ASP)	Approx. $54,300	Roughly flat sequentially

Looking forward, the company has set its expectations for the full fiscal year. The Full-year 2025 revenue guidance is between $40 million and $42 million. This guidance represents an expected growth of 23% to 29% versus 2024.

The current revenue streams can be summarized by the channels contributing to the top line:

• Sales via Direct Billing: 73% of Q3 2025 revenue.
• International Sales: 18% of Q3 2025 revenue.
• U.S. O&P Channel Sales: 9% of Q3 2025 revenue.

The shift is defintely visible; the O&P channel is emerging as a high-quality, lower-cost source of qualified patients, which is a key strategic focus for Myomo, Inc. (MYO).

Finance: draft 13-week cash view by Friday.